A striking approach was to cooperate Combretastatin A4 (CA4) nanodrug and matrix metalloproteinase 9 (MMP9)‐activated DOX prodrug NPs (Figure 10C); the prior use of CA4 aggravated the tumor hypoxia state, sequentially enhanced MMP9 expression by 5.6‐fold in tumors, hence enhance tumor‐selective active drug release by 3.7‐fold in animal model.[167]. The gene discussed is MMP9; the disease is neoplasm.